Drug-Drug Interaction Clinical Decision Support Conference Series

药物-药物相互作用临床决策支持会议系列

• 批准号: 8550787
• 负责人: DANIEL C MALONE
• 金额: $ 10万
• 依托单位: UNIVERSITY OF ARIZONA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-30 至 2015-09-29
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8550787
• 关键词: Drug; Interaction; Clinical; Decision; Support

DESCRIPTION (provided by applicant): Medications are essential to preventing and treating many illnesses. Americans receive an average of 12, and those aged 65 years and older receive more than 30 prescriptions each year. This degree of medication use creates the potential for drug-drug interactions (DDIs). Injury due to a known DDI is a preventable adverse drug event and serious medication error. Evidence suggests that hundreds of millions of interacting drugs are co-prescribed each year, ultimately exposing hundreds of millions of patients to these known hazards. Although the exact magnitude of harm associated with DDIs is not known, clinically significant interactions occur, resulting in potentially life-threatening consequences. Electronic prescribing and pharmacy information systems include DDI alerts as a form of clinical decision support (CDS) to warn prescribers and pharmacists of potentially harmful medication combinations, and provide them with necessary information to avoid or mitigate the risk of patient harm. Today, every pharmacy and soon every physician office and health care organization will employ some form of health information technology that will include DDI alerts. However, use of this technology to improve patient safety has not lived up to its promise. In particular, research has shown "the current DDI alert system is broken." This application requests partial support for a solution-oriented conference series aimed at improving the implementation of meaningful DDI alerts within CDS. The long- term goals are to develop an ongoing structured process to improve the quality of DDI alerting systems used by health providers to maximize the value of this technology, and ultimately improve patient safety. At these conferences, experts, stakeholders, and public-private partnerships will develop strategies for explicit, systematic evaluation of DDIs to improve knowledge base data and the practical utility of electronic clinical decision aids. Specific aims of the conference series are to: 1) develop guidelines for systematic appraisal of DDI evidence; 2) recommend principles for including DDIs in drug safety alerts; and 3) establish preferred strategies for presenting DDI alerts. In summary, this application will address an important public health issue regarding improving health information technology as a healthcare safety net, and will, ultimately lead to improved medication use and patient safety throughout the nation.

描述（由申请人提供）：药物对预防和治疗许多疾病至关重要。美国人平均每年收到12张处方，65岁及以上的人每年收到30多张处方。这种程度的药物使用产生了药物相互作用（DDI）的可能性。已知DDI导致的损伤是可预防的药物不良事件和严重用药错误。有证据表明，每年有数亿种相互作用的药物被共同处方，最终使数亿患者暴露于这些已知的危害。尽管与DDI相关的伤害的确切程度尚不清楚，但会发生具有临床意义的相互作用，导致潜在的危及生命的后果。电子处方和药房信息系统包括DDI警报，作为临床决策支持（CDS）的一种形式，以警告处方者和药剂师潜在有害的药物组合，并为他们提供必要的信息，以避免或减轻患者伤害的风险。今天，每家药店，很快每家医生办公室和医疗保健组织都将采用某种形式的健康信息技术，其中包括DDI警报。然而，使用这项技术来提高患者安全性并没有达到其承诺。特别是，研究表明“目前的DDI警报系统已经崩溃。“该应用程序请求对面向解决方案的系列会议提供部分支持，旨在改进CDS内有意义的DDI警报的实施。长期目标是开发一个持续的结构化过程，以提高医疗服务提供者使用的DDI警报系统的质量，从而最大限度地发挥该技术的价值，并最终提高患者安全性。在这些会议上，专家，利益相关者和公私合作伙伴关系将制定明确，系统评价DDI的战略，以改善知识库数据和电子临床决策辅助工具的实际效用。该系列会议的具体目标是：1）制定DDI证据系统评估指南; 2）建议将DDI纳入药物安全性警报的原则; 3）建立DDI警报的首选策略。总之，该应用程序将解决一个重要的公共卫生问题，即改善健康信息技术作为医疗保健安全网，并将最终导致改善全国的药物使用和患者安全。